Miochol-E 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään Suomi - suomi - Fimea (Suomen lääkevirasto)

miochol-e 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään

dr. gerhard mann chem.-pharm. fabrik gmbh - acetylcholine chloride - jauhe ja liuotin instillaatioliuosta varten, silmän sisään - 10 mg/ml - asetyylikoliini

Ultomiris Euroopan unioni - suomi - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Vyvgart Euroopan unioni - suomi - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - immunosuppressantit - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Bisolaclar 600 mg poretabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

bisolaclar 600 mg poretabletti

opella healthcare france sas - acetylcysteine - poretabletti - 600 mg - asetyylikysteiini

Mucomyst 200 mg poretabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

mucomyst 200 mg poretabletti

viatris oy - acetylcysteine - poretabletti - 200 mg - asetyylikysteiini

Equimucin vet 2 g jauhe Suomi - suomi - Fimea (Suomen lääkevirasto)

equimucin vet 2 g jauhe

cp-pharma handelsgesellschaft mbh - acetylcysteine - jauhe - 2 g - asetyylikysteiini

Meditus 200 mg poretabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

meditus 200 mg poretabletti

orion corporation - acetylcysteine - poretabletti - 200 mg - asetyylikysteiini

Mucoratio 200 mg poretabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

mucoratio 200 mg poretabletti

teva b.v. - acetylcysteine - poretabletti - 200 mg - asetyylikysteiini

Mucoratio 600 mg poretabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

mucoratio 600 mg poretabletti

teva b.v. - acetylcysteine - poretabletti - 600 mg - asetyylikysteiini

Stromease 25 mg/ml silmätipat, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

stromease 25 mg/ml silmätipat, liuos

domes pharma - acetylcysteine - silmätipat, liuos - 25 mg/ml - asetyylikysteiini